Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nina Andersen1,2, Ahmed Ludvigsen Al-Mashadi3, Emelie Hamotal Curovic Rotbain4

  • 1Hæmatologisk Afdeling, Odense Universitetshospital.

Ugeskrift for Laeger
|February 2, 2024
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes of patients with diffuse large B-cell lymphoma and concomitant rheumatoid arthritis: a nationwide Danish register-based cohort study.

EULAR rheumatology open·2026
Same author

Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population-Based Study of Patients With B-Cell Malignancies.

European journal of haematology·2026
Same author

Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma.

The Lancet. Haematology·2026
Same author

Validity of The Danish National Chronic Myeloid Neoplasia Registry.

Clinical epidemiology·2026
Same author

Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.

British journal of haematology·2026
Same author

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population-Based Study.

European journal of haematology·2026

Novel targeted therapies, including small molecules and monoclonal antibodies, have transformed blood cancer treatment for elderly patients. These well-tolerated options offer improved prognoses and are the current standard of care.

Area of Science:

  • Hematology
  • Oncology
  • Geriatric Medicine

Background:

  • Hematological cancers pose significant challenges, particularly in elderly populations.
  • Traditional treatments often have limitations for older adults.
  • Recent advancements offer new therapeutic avenues.

Approach:

  • This review summarizes current standard-of-care treatments for elderly patients with hematological malignancies.
  • Focuses on novel targeted therapies, including small molecules and monoclonal antibodies.
  • Highlights the tolerability and efficacy of these agents in the geriatric population.

Key Points:

  • Targeted therapies, such as oral small molecules and monoclonal antibodies, have significantly improved outcomes for hematological cancers.
  • These novel treatments are generally well-tolerated, making them suitable for elderly patients.

Related Experiment Videos

  • The review provides an update on the established treatment protocols for this demographic.

    • Conclusions:

    • Novel targeted therapies represent a paradigm shift in managing hematological cancers in the elderly.
    • These advancements enhance treatment efficacy and patient tolerance.
    • The current standard of care prioritizes these well-tolerated, effective therapeutic strategies.